Instrument Inactif

Communiqués Freeline Therapeutics Holdings plc

Actions

FRLN

US35655L2060

Recherche biotechnologique et médicale

Communiqués

24/04/24	Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	AQ
20/02/24	Acquisition of Freeline by Syncona Becomes Effective	AQ
12/02/24	Freeline Shareholders Approve Acquisition by Syncona	AQ
01/12/23	Freeline Therapeutics : Reports Second Quarter 2023 Financial Results and Business Highlights - Form 6-K	PU
28/11/23	FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN	BU
22/11/23	Syncona to Acquire Freeline Therapeutics	AQ
25/10/23	Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress	AQ
16/10/23	Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress	AQ
04/10/23	Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease	AQ
15/08/23	Freeline Reports Second Quarter 2023 Financial Results and Business Highlights	AQ
14/08/23	Freeline Therapeutics : Corporate Presentation	PU
08/08/23	Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call	AQ
02/08/23	Freeline Therapeutics : Corporate Presentation – July	PU
31/07/23	Freeline to Participate in Upcoming Investor Conferences	AQ
25/07/23	Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease	AQ
30/06/23	Freeline Therapeutics : Voting Results of Annual General Meeting - Form 6-K	PU
26/06/23	Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease	AQ
02/06/23	Freeline to Present at 2023 Jefferies Healthcare Conference	AQ
31/05/23	Freeline Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	PU
30/05/23	Freeline Reports First Quarter 2023 Financial Results and Business Highlights	AQ
22/05/23	Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease	AQ
12/05/23	Freeline Therapeutics : Completes ADS Ratio Change - Form 6-K	PU
12/05/23	Freeline Completes ADS Ratio Change	AQ
21/04/23	Freeline Announces Proposed ADS Ratio Change	AQ
21/04/23	Freeline Therapeutics : Announces Proposed ADS Ratio Change - Form 6-K	PU